On Trapped Air and Trapped Blood in Chronic Obstructive Pulmonary Disease

por Watz, Henrik
Publicado 2019

Sarcoidosis with involvement of the paranasal sinuses - a retrospective analysis of 12 biopsy-proven cases

por Kirsten, Anne-Marie, Watz, Henrik, Kirsten, Detlef
Publicado 2013

Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover st...

por Watz, Henrik, Mailänder, Claudia, Baier, Monika, Kirsten, Anne
Publicado 2016

NETopathic Inflammation in Chronic Obstructive Pulmonary Disease and Severe Asthma

por Uddin, Mohib, Watz, Henrik, Malmgren, Anna, Pedersen, Frauke
Publicado 2019

Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease - a randomized, multicenter, double-blind, placebo-co...

por Watz, Henrik, Krippner, Felix, Kirsten, Anne, Magnussen, Helgo, Vogelmeier, Claus
Publicado 2014

COPD: the patient perspective

por Jones, Paul W, Watz, Henrik, Wouters, Emiel FM, Cazzola, Mario
Publicado 2016

Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Di...

por Facius, Axel, Marostica, Eleonora, Gardiner, Philip, Watz, Henrik, Lahu, Gezim
Publicado 2018

Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis

por Watz, Henrik, Rickard, Kathleen, Rheault, Tara, Bengtsson, Thomas, Singh, Dave
Publicado 2020

A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD

por Singh, Dave, Martinez, Fernando J., Watz, Henrik, Bengtsson, Thomas, Maurer, Brian T.
Publicado 2020

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone

por Balint, Beatrix, Watz, Henrik, Amos, Carolynn, Owen, Roger, Higgins, Mark, Kramer, Benjamin
Publicado 2010

Decline of COPD exacerbations in clinical trials over two decades – a systematic review and meta-regression

por Andreas, Stefan, Röver, Christian, Heinz, Judith, Straube, Sebastian, Watz, Henrik, Friede, Tim
Publicado 2019

Effect of Inhaled Corticosteroid Withdrawal on Chronic Obstructive Pulmonary Disease Exacerbations in Patients Taking Triple Therapy at Baseline

por Ferguson, Gary T, Shaikh, Asif, Tetzlaff, Kay, Mueller, Achim, Magnussen, Helgo, Watz, Henrik
Publicado 2020

Constant-load exercise decreases the serum concentration of myeloperoxidase in healthy smokers and smokers with COPD

por Holz, Olaf, Roepcke, Stefan, Watz, Henrik, Tegtbur, Uwe, Lahu, Gezim, Hohlfeld, Jens M
Publicado 2015

Genetic evidence for a causative effect of airflow obstruction on left ventricular filling: a Mendelian randomisation study

por Harbaum, Lars, Hennigs, Jan K., Simon, Marcel, Oqueka, Tim, Watz, Henrik, Klose, Hans
Publicado 2021

Potential prognostic value of biomarkers in lavage, sputum and serum in a five year clinical follow-up of smokers with and without COPD

por Holz, Olaf, Waschki, Benjamin, Roepcke, Stefan, Watz, Henrik, Lauer, Gereon, Faulenbach, Cornelia, Hohlfeld, Jens M
Publicado 2014

Rating sputum cell quality in clinical trials for asthma and COPD treatment

por Pedersen, Frauke, Zissler, Ulrich M, Watz, Henrik, Rabe, Klaus F, Hohlfeld, Jens M, Holz, Olaf
Publicado 2019

Clinical Implications of Peak Inspiratory Flow in COPD: Post Hoc Analyses of the TRONARTO Study

por Mahler, Donald A, Watz, Henrik, Emerson-Stadler, Rachel, Ritz, John, Gardev, Asparuh, Shaikh, Asif, Drummond, M Bradley
Publicado 2023

Effects of pharmacological and non-pharmacological interventions on physical activity outcomes in COPD: a systematic review and meta-analysis

por Megaritis, Dimitrios, Hume, Emily, Chynkiamis, Nikolaos, Buckley, Christopher, Polhemus, Ashley M., Watz, Henrik, Troosters, Thierry, Vogiatzis, Ioannis
Publicado 2023

Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function

por Waschki, Benjamin, Watz, Henrik, Holz, Olaf, Magnussen, Helgo, Olejnicka, Beata, Welte, Tobias, Rabe, Klaus F, Janciauskiene, Sabina
Publicado 2017

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat(®) device for maintenance treatment of COPD: comparison with the long-acting β(2)-agonist formoterol

por Koch, Andrea, Watz, Henrik, Maleki-Yazdi, M. Reza, Bothner, Ulrich, Tetzlaff, Kay, Voß, Florian, McGarvey, Lorcan
Publicado 2017